<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Biovail Corp. | Company News & Executive Profiles - BVF | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/biovail+corp..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Biovail Corp.]]></description>
	<s:counts start="0" returned="10" found="640" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Biovail VP: If Cardizem Reps Don't Deliver, "My Net Worth Will Shrink Dramatically"]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004307/biovail-vp-if-cardizem-reps-dont-deliver-my-net-worth-will-shrink-dramatically/]]></link>
		<description><![CDATA[The news that the company will pay $25 million in fines for bribing doctors into prescribing the blood pressure drug Cardizem turns out to be just the tip of the iceberg. Stock fraud and misrepresentation to shareholders is all part of the mix. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 16 Sep 2009 08:44:05 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">BVF</category>
	</item>
	<item>
		<title><![CDATA[Take Advantage of Biovail Weakness - RBC]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159605-take-advantage-of-biovail-weakness-rbc%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[FP Trading Desk submits:  Investors should take advantage of Biovail Corp.'s BVF falling stock price on Tuesday, says Douglas Miehm, RBC Capital Markets analyst.  Shares in the Canadian pharmaceutical company fell almost 2% or 25¢ to C$13.74 on Tuesday after the company announced a failed trial of a...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 02 Sep 2009 06:07:05 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/fp+trading+desk.html"><![CDATA[FP Trading Desk]]></category>
		<category domain="http://resources.bnet.com/topic/acadia+pharmaceuticals+inc..html"><![CDATA[Acadia Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACAD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">ACAD,BVF</category>
	</item>
	<item>
		<title><![CDATA[A (Bio)Vail of Tears: Junk Lawsuit Against SAC Capital Thrown Out]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F157872-a-bio-vail-of-tears-junk-lawsuit-against-sac-capital-thrown-out%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Gary Weiss submits:  There was weeping and wailing and blubbering among inept CEOs across the land in recent days as a federal court judge threw out a junk lawsuit against hedge fund manager SAC Capital Advisors and Gradient Analytics by the veteran underperforming blame-shifter, Biovail Corp BVF.In retrospect it...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 24 Aug 2009 01:58:03 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/gary+weiss.html"><![CDATA[Gary Weiss]]></category>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">BVF</category>
	</item>
	<item>
		<title><![CDATA[Biovail: Drug Ruling Not Expected to Have Significant Impact - RBC]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F157047-biovail-drug-ruling-not-expected-to-have-significant-impact-rbc%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[FP Trading Desk submits:  A recent U.S. district court ruling that allows a rival pharmaceutical company to produce its own version of a generic painkiller will cut into the market share of Biovail Corp. BVF, but RBC Capital Markets does not expect a significant impact on the Canadian drug...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 19 Aug 2009 07:21:32 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/fp+trading+desk.html"><![CDATA[FP Trading Desk]]></category>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">BVF</category>
	</item>
	<item>
		<title><![CDATA[Biovail Acquisition: UBS Approves, Paradigm Calls It 'A Little Expensive']]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F138483-biovail-acquisition-ubs-approves-paradigm-calls-it-a-little-expensive%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[FP Trading Desk submits:  Biovail Corp. BVF struck a $200-million deal Monday to acquire worldwide rights for Tetrabenzene products, which treat Huntington's disease, and analysts consider it to be a logical move for the Toronto-based drugmaker. After all, Biovail already owned the marketing rights in Canada and the United...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 19 May 2009 09:23:26 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/fp+trading+desk.html"><![CDATA[FP Trading Desk]]></category>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">BVF</category>
	</item>
	<item>
		<title><![CDATA[Biovail 'Still Not Getting the Attention It Deserves' - UBS]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F135387-biovail-still-not-getting-the-attention-it-deserves-ubs%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[FP Trading Desk submits:  Biovail Corp.'s BVF latest rights acquisition is right on strategy, but whether it proves profitable will likely remain unknown for some time to come, says UBS analyst Marc Goodman. On Monday, Biovail entered into an agreement with Acadia Pharmaceuticals Inc. ACAD, to co-develop Acadia's experimental...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 05 May 2009 10:39:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/fp+trading+desk.html"><![CDATA[FP Trading Desk]]></category>
		<category domain="http://resources.bnet.com/topic/acadia+pharmaceuticals+inc..html"><![CDATA[Acadia Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACAD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">ACAD,BVF</category>
	</item>
	<item>
		<title><![CDATA[Biovail: Upside Potential, High Dividend Yield]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F123402-biovail-upside-potential-high-dividend-yield%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Quarterly Result Summary:           Revenue fell to $181.5 million from $203.9 million a year earlier, hurt by declining sales of key treatments.Considers nominating new members to the board and change some corporate governance provisions.76 cents a share, during the quarter, compared...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Sun, 01 Mar 2009 09:35:52 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/chris+lau.html"><![CDATA[Chris Lau]]></category>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">BVF</category>
	</item>
	<item>
		<title><![CDATA[Biovail Corporation Q2 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-236952.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Thank you, sir; we will now take questions from the listeners. Operator Instructions  The first question&#8217;s from Randall Stanicky - Goldman Sachs. Randall Stanicky - Goldman Sachs Great, thanks a lot for the question.  Bill, just a question first on the uses of...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 24 Sep 2008 17:41:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">BVF</category>
	</item>
	<item>
		<title><![CDATA[Analysts Express Confidence in Biovail's New Strategy]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F96271-analysts-express-confidence-in-biovail-s-new-strategy%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[FP Trading Desk submits:  Biovail Corp.'s BVF acquisition of Prestwick Pharmaceuticals on Wednesday may not have been well received by investors, but according to RBC Capital analyst Douglas Miehm, it is a move in the right direction for the pharmaceutical company in transition.  On Wednesday, Biovail said it bought...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 18 Sep 2008 11:51:30 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">BVF</category>
	</item>
	<item>
		<title><![CDATA[RBC Likes Biovail's Strategy Shift]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F90975-rbc-likes-biovail-s-strategy-shift%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[FP Trading Desk submits:  RBC Capital Markets analyst Doug Miehm offered qualified support for drug maker Biovail Corp.'s BVF much talked about strategic shift into central nervous system drugs, praising management in a note this morning for doing "a good job" of explaining the new focus. However, in a...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 14 Aug 2008 10:05:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biovail+corp..html"><![CDATA[Biovail Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BVF</category>
		<category domain="tickers">BVF</category>
	</item>
</channel>
</rss>
